NCT05095038终止不适用
A Six Month Randomized Placebo-controlled Trial of Appethyl® vs Placebo in Management of Pre-diabetes on Overweight and Obese Individuals
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 82
- 试验地点
- 2
- 主要终点
- Fasting blood glucose
研究概览
简要总结
The study will be conducted as a 26-week double-blinded randomized placebo-controlled trial of Appethyl® vs placebo in 100 overweight/obese (BMI ≥25.0-35.9 kg/m^2) men and women between 18-65 years with prediabetes (fasting plasma glucose of 5.6 mmol/L to <7.0 mmol/L). At initiation, all subjects will receive healthy life style instructions in accordance to the guidelines described in the Nordic Nutrition Recommendations.
The study aim to investigate the effect over time (26-weeks) of daily Appethyl® treatment compared to placebo on change in fasting glucose (primary endpoint) and several other health markers (secondary endpoint).
The hypothesis to be tested is whether the null hypothesis (no difference between Appethyl® and placebo with regard to endpoint data) can be rejected.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and women Age between 18-65 years
- •BMI ≥25.0-35.9 kg/m^2
- •Prediabetes (defined according to ADA with a fasting plasma glucose of 5.6 mmol/L to <7.0 mmol/L)
- •Provided voluntary written informed consent
排除标准
- •Non-covid-19 vaccinated
- •Known diseases which may affect energy expenditure and/or satiation/satiety/food intake
- •History or diagnosis of eating disorder
- •Any physical abnormality or medical condition which might have impact on following the dietary regimen
- •Psychiatric disorders i.e. schizophrenia, bipolar disease or depression with hospitalization within the last 6 months
- •Diabetes mellitus (type 1 and 2)
- •History or diagnosis of cardiovascular disease, chronic kidney disease, liver disease and cancer
- •Known systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg whether on or off treatment for hypertension. If being treated, stable treatment (i.e. no change in treatment, either dose, type of medication or other changes) within last three months is required
- •Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption
- •Systemic treatment with glucocorticoids inhalations and creams etc. is allowed
- •Previous bariatric surgery or intention to undergo bariatric surgery within the next 12 months
- •History of extensive small or large bowel resection
- •Known endocrine origin of obesity (except for treated hypothyroidism)
- •Transmissible blood-borne diseases e.g. hepatitis B, HIV
- •Any recent surgical procedure not fully recovered (as judged by the investigator)
- •Current use of prescription medication or use within the previous month that has the potential of affecting body weight
- •Current use of other prescription medication that does not affect body weight should have been stable for the past three months and expected to be stable during the study
- •Concurrent therapy with immunosuppressive drugs or cytotoxic agents
- •Hemoglobin concentration below local laboratory reference values (i.e. anemia)
- •Being lactating, pregnant or planning to become pregnant within the study period
- •Weight changes ± 5% three months prior inclusion
- •Dietary patterns interfering with the study protocol, as judged by the investigator, two months prior inclusion, during the study or plans to initiate during the study
- •Use of pre- and probiotic products (incl. fiber supplements) within one month prior to study initiation as well as during the study (except psyllium 10 g/day)
- •Use of dietary supplementation should be stable three months prior to study initiation as well as during the study
- •Severe food allergies and food intolerances expected to interfere with the study
- •Intolerance, allergy or dislike of intervention products (e.g. pea allergy)
- •Engagement in elite sports or similar strenuous exercise ≥5 h/week
- •Blood donation or transfusion within the past month before screening
- •Planned blood donation for other purpose than this study during participation
- •Consumption of alcohol corresponding to >2 (for men) and >1 (for women) units/day
- •Drug abuse, as judged by the investigator, within the previous 12 months
- •Psychological or behavioral problems which, in the judgement of the investigator, would lead to difficulty in complying with the study protocol
- •Participation in other clinical trials within the past three months or intention to do so during the study, which are likely to affect the present study
- •Unable to consume the interventional product for religious reasons, swallowing disorders, other physiological reasons or any other reasons for not being able to follow the recommended diet
- •Inability or unwillingness to give written informed consent or communicate with study personnel
- •Inability or unwillingness to follow the study protocol and instructions given by the study personnel
- •Illiteracy or inadequate understanding of Danish/Scandinavia
- •Any other condition that judged by the investigator may interfere with the adherence to the study protocol
结局指标
主要结局
Fasting blood glucose
时间窗: Change from baseline (week 0) to end of intervention (week 26)
To investigate the effect over time of daily Appethyl® treatment compared to placebo on change in fasting glucose.
次要结局
- Change in anthropometrics(Change from baseline (week 0) to end of intervention (week 26))
- Change in fasting Insulin(Change from baseline (week 0) to end of intervention (week 26))
- Change in inflammation(Change from baseline (week 0) to end of intervention (week 26))
- Change in pulse(Change from baseline (week 0) to end of intervention (week 26))
- Change in bodyweight(Change from baseline (week 0) to end of intervention (week 26))
- Change in body composition(Change from baseline (week 0) to end of intervention (week 26))
- Change in subjective assessment of dietary preferences(Change from baseline (week 0) to end of intervention (week 26))
- Change in hbA1c(Change from baseline (week 0) to end of intervention (week 26))
- Change in blood lipids(Change from baseline (week 0) to end of intervention (week 26))
- Change in blood pressure(Change from baseline (week 0) to end of intervention (week 26))
- Change in the proportion of participants converting to normoglycemia(Change from baseline (week 0) to end of intervention (week 26))
- Change in subjective assessment of investigational product(Change from baseline (week 0) to end of intervention (week 26))
研究者
Faidon Magkos
Principal Investigator, Associate Professor
University of Copenhagen
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese SubjectsObesityNCT03041792Pfizer61
已完成
3 期
Lurasidone Pediatric Autism StudyAutismNCT01911442Sumitomo Pharma America, Inc.150
已完成
2 期
Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT01581034Insel Gruppe AG, University Hospital Bern80
已完成
1 期
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette SmokingHealthy VolunteersNCT01518985Stealth BioTherapeutics Inc.6
已完成
2 期
Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisIPFIdiopathic Pulmonary FibrosisNCT02503657MediciNova15